Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05132062 · ClinicalTrials.gov registry record
Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 14,616
- Enrollment target
NCT05132062 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 14,616 participants.
The verdict
NCT05132062 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 14,616 participants
- Enrollment target
Study Summary
Consecutive patients having percutaneous coronary intervention (PCI) over a period of 9 years at a large tertiary care center with available creatinine measurements both before and within 48 hours after the procedure were included; patients on chronic dialysis were excluded. Patients treated between 2012 and 2017 comprised the derivation cohort (n=14,616) and those treated from 2018 to 2020 formed the validation cohort (n=5,606). The primary endpoint is contrast-associated acute kidney injury (CA-AKI, defined per Acute Kidney Injury Network \[AKIN\]). In addition, independent predictors of CA-AKI will be derived from multivariate logistic regression analysis. Model 1 will include only preprocedural variables, while Model 2 will also include procedural variables. A weighted integer score based on the effect estimate of each independent variable will be used to calculate the final risk score for each patient. Impact on 1-year mortality will be also evaluated.
Interventions
- PROCEDURE Percutaneous Coronary Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,616 participants |
| Start Date | 2012-01-01 |
| Est. Completion | 2021-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05132062
The ClinicalTrials.gov registry entry for NCT05132062 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14,616 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Percutaneous Coronary Intervention is the first listed.
NCT05132062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05132062 about?
NCT05132062 is a clinical study titled "Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI". Consecutive patients having percutaneous coronary intervention (PCI) over a period of 9 years at a large tertiary care center with available creatinine measurements both before and within 48 hours after the procedure were included; patients on chronic dialysis were excluded. Patients treated between...
What is the current status of trial NCT05132062?
This trial is currently completed. The enrollment target is 14,616 participants. The study started on 2012-01-01. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT05132062?
The interventions under investigation include: Percutaneous Coronary Intervention (PROCEDURE).
Who is sponsoring clinical trial NCT05132062?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.